Karyopharm Therapeutics (KPTI) Interest Expenses (2012 - 2026)

Karyopharm Therapeutics (KPTI) has 14 years of Interest Expenses data on file, last reported at $12.6 million in Q4 2025.

• Quarterly Interest Expenses rose 12.63% year-over-year to $12.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $46.0 million (up 23.04% YoY) and the FY2025 annual result came in at $312.8 million, down 29.97% from the prior year.
• Interest Expenses fell to $12.6 million in Q4 2025, from $55.1 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $55.1 million in Q3 2025 to a low of $2.6 million in Q4 2021.
• A 5-year average of $10.4 million and a median of $6.5 million in 2022 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2022 — Interest Expenses soared 692.93% — and 2023, when it slumped 87.39%.
• Tracing KPTI's Interest Expenses over 5 years: stood at $2.6 million in 2021, then soared by 692.93% to $20.5 million in 2022, then plunged by 87.39% to $2.6 million in 2023, then jumped by 333.09% to $11.2 million in 2024, then climbed by 12.63% to $12.6 million in 2025.
• The last three Interest Expenses figures came in at $12.6 million (Q4 2025), $55.1 million (Q3 2025), and $11.2 million (Q2 2025), per Business Quant data.